Gossamer Bio Advances Toward NDA Submission for Seralutinib, Reacquires Global Rights, and Strengthens Strategic Position
Gossamer Bio, Inc. (Nasdaq: GOSS), a clinical-stage biopharmaceutical company dedicated to developing innovative treatments for pulmonary hypertension, has announced a series of significant regulatory, strategic, and corporate milestones that reinforce its position as it prepares for the potential commercialization of its lead investigational therapy, seralutinib. The updates include positive regulatory interactions with the U.S. Food and Drug Administration (FDA), the reacquisition of worldwide development and commercialization rights for seralutinib, shareholder approval of important financial restructuring initiatives, and a strengthened financial outlook.
Collectively, these developments mark an important period for the company as it advances toward submitting a New Drug Application (NDA) for seralutinib in pulmonary arterial hypertension (PAH), while positioning itself for long-term global growth.
Advancing Toward Regulatory Submission
The most significant announcement from Gossamer is its continued progress toward filing an NDA for seralutinib for the treatment of pulmonary arterial hypertension.
Following a productive Pre-NDA Type B meeting with the FDA and receipt of the agency’s official meeting minutes, the company confirmed that it remains on track to submit its NDA in September 2026.
The FDA meeting served as an important opportunity for Gossamer to discuss the clinical data package, regulatory expectations, and submission strategy for seralutinib. According to the company, the FDA’s feedback provided greater clarity regarding the overall review pathway and confirmed that the agency’s questions relate primarily to review considerations rather than filing eligibility.
Gossamer intends to support its NDA using evidence from:
- The Phase 3 PROSERA trial
- The Phase 2 TORREY study
- Additional supportive analyses and confirmatory data
If accepted for review, the NDA could position seralutinib for a potential FDA approval decision during the third quarter of 2027.
Although the FDA will ultimately determine approvability after reviewing the complete application, the company believes its current regulatory interactions provide confidence to proceed according to its planned timeline.
A Potential First-in-Class Therapy
Seralutinib is an inhaled investigational therapy designed to inhibit several important signaling pathways involved in pulmonary vascular remodeling.
The drug targets:
- Platelet-derived growth factor receptor (PDGFR)
- Colony-stimulating factor 1 receptor (CSF1R)
- c-KIT
These molecular targets are believed to contribute significantly to the pathological remodeling of pulmonary blood vessels that characterizes pulmonary arterial hypertension.
Unlike therapies that primarily address symptoms through vasodilation, seralutinib has been developed with the objective of modifying the underlying disease biology by reducing abnormal cell proliferation, inflammation, and vascular remodeling.
If approved, seralutinib could represent one of the first therapies specifically designed to address disease progression rather than simply improving pulmonary blood flow.
CEO Highlights Company’s Progress
Faheem Hasnain, Chairman, Co-Founder, and Chief Executive Officer of Gossamer Bio, described the recent achievements as transformational for the organization.
He emphasized that the company now possesses a clearer regulatory pathway following extensive discussions with the FDA and expressed confidence in moving toward its planned NDA submission.
According to Hasnain, years of disciplined clinical development have brought the company closer than ever to introducing what it believes could become an important new treatment option for patients living with pulmonary arterial hypertension.
He also noted that reacquiring worldwide rights to seralutinib significantly strengthens Gossamer’s strategic flexibility and allows the company to capture substantially greater long-term value from the program.
Global Rights Return to Gossamer
One of the company’s most notable strategic announcements involves the termination of its previous collaboration and licensing agreement with Chiesi.
As part of the new agreement, Gossamer has regained worldwide development and commercialization rights for seralutinib.
This strategic move provides several important advantages.
The company now has complete operational control over:
- Global clinical development
- Regulatory strategy
- Manufacturing
- Commercial planning
- Pricing decisions
- Product lifecycle management
- Future indication expansion
Previously, Gossamer shared U.S. economics through a profit-sharing arrangement while receiving royalties in international markets.
Following the restructuring, the company retains the substantial majority of the program’s future economic value.
Financial Terms of the Agreement
The revised agreement with Chiesi includes several favorable financial provisions.
Rather than paying an upfront fee to reacquire the rights, Gossamer will instead receive a one-time payment of $5 million from Chiesi shortly after execution of the agreement.
The payment also resolves all remaining obligations under the former collaboration, including outstanding second-quarter 2026 expenses.
In return, Chiesi will remain eligible to receive:
- Certain regulatory milestone payments
- Commercial milestone payments
- A capped royalty based on worldwide net sales
Once the royalty cap is reached, no further royalty obligations will apply.
This structure allows Gossamer to maintain the overwhelming majority of long-term commercial economics while simplifying future royalty obligations.
Confidence in Future Indications
Although pulmonary arterial hypertension remains the immediate focus, Gossamer believes seralutinib may have broader applications.
The company continues evaluating opportunities in:
- Pulmonary hypertension associated with interstitial lung disease (PH-ILD)
- Additional pulmonary vascular disorders
- Other future indications where its multi-target mechanism may offer therapeutic benefit
Maintaining full ownership of worldwide rights provides greater flexibility to pursue these opportunities independently.
Shareholders Approve Financial Restructuring
Gossamer also announced the successful completion of several shareholder-approved corporate initiatives during a recent special meeting.
Investors approved proposals related to:
- The previously completed convertible note exchange
- Authorization for a reverse stock split
- Additional related corporate governance measures
These approvals provide the company with increased financial flexibility while supporting its regulatory and commercialization objectives.
Convertible Debt Exchange Improves Balance Sheet
A major component of Gossamer’s financial restructuring involved exchanging a substantial portion of its outstanding convertible debt.
Approximately $181.1 million—or more than 90%—of the company’s outstanding 2027 Convertible Senior Notes were exchanged for:
- Approximately $65.2 million of new secured convertible notes due in 2030
- Equity securities
- Warrants
As a result, Gossamer reduced its outstanding debt principal by nearly $116 million.
The transaction substantially strengthens the company’s balance sheet while lowering future financial obligations.
Only approximately $18.9 million of the original 2027 notes remain outstanding.
Management believes this improved capital structure provides greater flexibility as the company transitions toward potential commercialization.
Reverse Stock Split Authorization
Shareholders also authorized the Board of Directors to implement a reverse stock split if deemed appropriate.
The reverse split is expected to:
- Support continued compliance with Nasdaq listing requirements
- Improve share structure
- Enhance financial flexibility
The company anticipates implementing the reverse split during or shortly after the third quarter of 2026, although the final timing and ratio remain subject to board approval.
Cash Position Supports Ongoing Operations
Gossamer reported preliminary financial results indicating that cash, cash equivalents, and marketable securities totaled approximately $57 million as of June 30, 2026.
Combined with its recent debt restructuring, management believes this financial position provides a stronger foundation for:
- NDA preparation
- Regulatory activities
- Commercial readiness
- Continued clinical development
The improved financial outlook is expected to support the company’s key milestones over the coming year.
Building Momentum Toward Commercialization
The combination of positive regulatory feedback, strengthened financial resources, and full ownership of seralutinib positions Gossamer for what may become the company’s most significant phase since its founding.
Management believes the program has matured from a promising clinical asset into a potential commercial opportunity capable of addressing an important unmet medical need in pulmonary arterial hypertension.
With complete control over global strategy, the company can now independently manage regulatory submissions, future partnerships, manufacturing scale-up, and commercialization planning.
Several important milestones are expected over the next 12 to 18 months.
The company plans to submit its NDA for seralutinib in September 2026. If accepted, regulatory review could lead to a potential FDA decision during the third quarter of 2027. At the same time, Gossamer will continue advancing development opportunities beyond PAH while leveraging its restored global rights to maximize the long-term value of seralutinib.
By combining encouraging regulatory progress, stronger financial positioning, streamlined ownership of its lead asset, and continued clinical momentum, Gossamer Bio has entered a pivotal stage in its evolution. As the company moves toward potential commercialization, it aims to establish seralutinib as an innovative treatment option for patients with pulmonary arterial hypertension while creating additional opportunities across broader pulmonary vascular diseases.
About Gossamer Bio
Gossamer Bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease. Its goal is to be an industry leader in, and to enhance the lives of patients living with, pulmonary hypertension.